Careers Open Positions Benefits Contact Us Menu ALEXZA PHARMACEUTICALS PIPELINE OPPORTUNITIES Current partners and available partnership opportunities Through licensing relationships, research collaborations and strategic alliances that complement and extend the Staccato technology, Alexza is interested in collaborations that have the potential to create superior products and improve patients’ lives. Commercial product ADASUVE® Staccato® loxapine For the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults Ferrer holds commercial rights in Europe, Latin America, Russia, the CIS countries, the Middle East and North Africa countries, Korea, the Philippines, and Thailand Lee’s Pharm holds commercial rights in China Commercial opportunity for the US is available Available for licensing in all other territories Active programs in development with partners Staccato® alprazolam For the acute treatment of epileptic seizures UCB holds worldwide development and commercial rights Active programs led by Alexza Staccato® apomorphine For the rapid, acute treatment of OFF episodes in patients with Parkinson’s disease on stable anti-Parkinson medication Staccato® granisetron For the acute treatment of cyclic vomiting syndrome To see our pipeline click here. For more information about our programs click here. To discuss partnership and licensing opportunities, please contact our Business Development Group. ©2021 ALEXZA® ALEXZA PHARMACEUTICALS Corporate Headquarters 2091 Stierlin Court Mountain View, CA 94043 TEL: 650 944 7000 FAX: 650 944 7999 About Pipeline Partnering Contact Us Privacy Policy Terms of Use Disclaimer Staccato OBT